Biovie Inc (NASDAQ:BIVI) shares surged 7.3% after unveiling encouraging results for its Alzheimer’s treatment bezisterim at a recent conference in Rome.
The clinical-stage biotech firm reported that bezisterim significantly slowed biological aging in Alzheimer’s patients compared to placebo during its Phase 3 trial. After 30 weeks, treated patients showed age deceleration of up to 4.24 years across several biological aging markers.
These findings were shared at the 2nd World Conference on Aging and Gerontology held July 14-15, 2025, in Rome, based on analysis of 33 blood samples from the Phase 3 NM101 study evaluating bezisterim in mild-to-moderate probable Alzheimer’s disease patients.
Besides its effects on age deceleration, bezisterim also appeared to influence gene expression linked to inflammation, reducing levels of inflammatory cytokines. It showed potential positive modulation of genes involved in aging and Alzheimer’s disease pathways.
Patients on bezisterim experienced notable improvements in metabolic and inflammatory biomarkers versus placebo, including decreases in fasting glucose (-8.5 mg/dL), cholesterol (-15 mg/dL), and MCP (-90.5 pg/mL).
Bezisterim is a stabilized form of Beta AET, a natural brain metabolite that diminishes with age. Unlike the natural molecule, bezisterim is metabolically stable, orally bioavailable, and crosses the blood-brain barrier.
The company is continuing studies to validate these results and to assess bezisterim’s potential to enhance healthspan in normal aging.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.